Literature DB >> 33489173

Successful treatment of adult-onset nesidioblastosis by continuous subcutaneous octreotide infusion in a patient on hemodialysis.

Rina Kato1, Akihiro Nishimura1, Kimio Matsumura1, Shota Kikuno1, Kaoru Nagasawa1, Yasumichi Mori1.   

Abstract

Octreotide may be useful in noninsulinoma pancreatogenous hypoglycemia syndrome with nesidioblastosis patients who was on hemodialysis. Continuous octreotide subcutaneous infusion can reduce side-effects and stabilize plasma glucose levels.
© 2020 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd.

Entities:  

Keywords:  hemodialysis; nesidioblastosis; octreotide

Year:  2020        PMID： 33489173      PMCID： PMC7813030          DOI： 10.1002/ccr3.3514

Source DB:  PubMed          Journal:  Clin Case Rep        ISSN： 2050-0904


  13 in total

1.  Selective Arterial Calcium Stimulation With Hepatic Venous Sampling Differentiates Insulinoma From Nesidioblastosis.

Authors:  Scott M Thompson; Adrian Vella; Geoffrey B Thompson; Kandelaria M Rumilla; F John Service; Clive S Grant; James C Andrews
Journal:  J Clin Endocrinol Metab       Date:  2015-08-27       Impact factor: 5.958

2.  Insulinoma in a patient with chronic renal failure due to type 2 diabetes mellitus treated effectively with diazoxide.

Authors:  Masanori Shimizu; Kunihiro Suzuki; Kohei Tsuchida; Masaru Kojima; Hideyuki Hiraishi; Yoshimasa Aso
Journal:  Intern Med       Date:  2015-01-15       Impact factor: 1.271

3.  Management of hyperinsulinemia with diazoxide in an elderly hemodialysis patient.

Authors:  A J Shaer
Journal:  Nephron       Date:  2001-11       Impact factor: 2.847

Review 4.  Octreotide.

Authors:  S W Lamberts; A J van der Lely; W W de Herder; L J Hofland
Journal:  N Engl J Med       Date:  1996-01-25       Impact factor: 91.245

Review 5.  Adult-onset nesidioblastosis causing hypoglycemia: an important clinical entity and continuing treatment dilemma.

Authors:  R M Witteles; F H Straus II; S L Sugg; M R Koka; E A Costa; E L Kaplan
Journal:  Arch Surg       Date:  2001-06

6.  Efficacy and safety of long-term, continuous subcutaneous octreotide infusion for patients with different subtypes of KATP-channel hyperinsulinism.

Authors:  Tohru Yorifuji; Rie Kawakita; Yuki Hosokawa; Rika Fujimaru; Kousaku Matsubara; Katsuya Aizu; Shigeru Suzuki; Hironori Nagasaka; Hironori Nishibori; Michiya Masue
Journal:  Clin Endocrinol (Oxf)       Date:  2013-04-06       Impact factor: 3.478

7.  A rare case of adult-onset nesidioblastosis treated successfully with diazoxide.

Authors:  Tadashi Arao; Yosuke Okada; Akiko Hirose; Yoshiya Tanaka
Journal:  Endocr J       Date:  2006-02       Impact factor: 2.349

8.  Plasma insulin is removed by hemodialysis: evaluation of the relation between plasma insulin and glucose by using a dialysate with or without glucose.

Authors:  Masanori Abe; Kazo Kaizu; Koichi Matsumoto
Journal:  Ther Apher Dial       Date:  2007-08       Impact factor: 1.762

9.  Hypoglycemia with hyperinsulinemia in a chronic hemodialysis patient following parathyroidectomy.

Authors:  M Nadkarni; J S Berns; M R Rudnick; R M Cohen
Journal:  Nephron       Date:  1992       Impact factor: 2.847

10.  Clinical practice guidelines for congenital hyperinsulinism.

Authors:  Tohru Yorifuji; Reiko Horikawa; Tomonobu Hasegawa; Masanori Adachi; Shun Soneda; Masanori Minagawa; Shinobu Ida; Takeo Yonekura; Yoshiaki Kinoshita; Yutaka Kanamori; Hiroaki Kitagawa; Masato Shinkai; Hideyuki Sasaki; Masaki Nio
Journal:  Clin Pediatr Endocrinol       Date:  2017-07-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.